imlygichcp.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | IMLYGIC® (talimogene laherparepvec) Oncolytic Viral |
| Description | Inject the lesion. Trigger an immune response. That’s the precision of Find information about IMLYGIC® (talimogene laherparepvec), including details about administration, storage, safety information and |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 44.239.241.199 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
imlygichcp.com Valuation
|
US$3,555,924
Last updated: 2023-05-15 17:03:06
imlygichcp.com has Semrush global rank of 2,976,527. imlygichcp.com has an estimated worth of US$ 3,555,924, based on its estimated Ads revenue. imlygichcp.com receives approximately 410,299 unique visitors each day. Its web server is located in United States, with IP address 44.239.241.199. According to SiteAdvisor, imlygichcp.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$3,555,924 |
| Daily Ads Revenue | US$3,283 |
| Monthly Ads Revenue | US$98,472 |
| Yearly Ads Revenue | US$1,181,661 |
| Daily Unique Visitors | 27,354 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| imlygichcp.com. | A | 59 | IP: 44.239.241.199 |
| imlygichcp.com. | A | 59 | IP: 44.239.177.5 |
| imlygichcp.com. | NS | 86400 | NS Record: ns-662.awsdns-18.net. |
| imlygichcp.com. | NS | 86400 | NS Record: ns-10.awsdns-01.com. |
| imlygichcp.com. | NS | 86400 | NS Record: ns-1325.awsdns-37.org. |
| imlygichcp.com. | NS | 86400 | NS Record: ns-1952.awsdns-52.co.uk. |
| imlygichcp.com. | MX | 300 | MX Record: 3 amgen-com.mail.protection.outlook.com. |
HtmlToTextCheckTime:2023-05-15 17:03:06
| INDICATION & LIMITATIONS OF USE IMLYGIC ® (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery... READ MORE IMLYGIC ® (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC ® has not been shown to improve overall survival or have an effect on visceral metastases. Visit Patient Site Prescribing Information Medication Guide Indication Important Safety Information References FAQ Downloads Visit Patient Site Efficacy Efficacy OPTiM Pivotal Trial Durable & Overall Responses Time to Response Examples of Actual Results Hypothetical Patient Profiles View complete response rates from the OPTiM Pivotal Trial Safety Dosing & |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Thu, 06 Jan 2022 08:30:40 GMT Content-Type: text/html Content-Length: 520 Connection: keep-alive |
imlygichcp.com Whois Information
Domain Name: IMLYGICHCP.COM Registry Domain ID: 1861715561_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2020-05-04T09:09:40Z Creation Date: 2014-06-05T18:51:18Z Registry Expiry Date: 2022-06-05T18:51:18Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-10.AWSDNS-01.COM Name Server: NS-1325.AWSDNS-37.ORG Name Server: NS-1952.AWSDNS-52.CO.UK Name Server: NS-662.AWSDNS-18.NET DNSSEC: unsigned >>> Last update of whois database: 2022-01-06T08:07:14Z <<< |